SCHEMBL22836201

SCHEMBL22836201

CC(N)SSC(C)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.42
TP53 P04637 1/20 0.36
ALDH1A1 P00352 2/20 0.34
HSD17B10 Q99714 1/20 0.34
SLC1A3 P43003 2/20 0.33
SLC1A2 P43004 2/20 0.33
SLC1A1 P43005 1/20 0.33
BHMT Q93088 1/20 0.32
BHMT2 Q9H2M3 1/20 0.32
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
ENPEP Q07075 2/20 0.32
GABRP O00591 4/20 0.32
GABRD O14764 4/20 0.32
GABRA1 P14867 4/20 0.32
GABRB1 P18505 4/20 0.32
GABRG2 P18507 4/20 0.32
GABRB3 P28472 4/20 0.32
GABRA5 P31644 4/20 0.32
GABRA3 P34903 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL95981 0.86 TP53 (0.47) SLC7A5TP53ALDH1A1HSD17B10KDM4E
Ammonia Solution, Strong SCHEMBL8958635 0.83 TP53 (0.44) SLC7A5TP53ALDH1A1HSD17B10KDM4E
SCHEMBL11317937 0.83 TP53 (0.44) SLC7A5TP53ALDH1A1HSD17B10KDM4E
Hydrogen Sulfide SCHEMBL9001004 0.83 TP53 (0.44) SLC7A5TP53ALDH1A1HSD17B10KDM4E
Acetic Acid SCHEMBL6932728 0.80 FFAR3 (0.44) SLC7A5TP53ALDH1A1HSD17B10KDM4E
Acetic Acid SCHEMBL20593502 0.78 FFAR3 (0.41) SLC7A5TP53ALDH1A1HSD17B10KDM4E
SCHEMBL16303293 0.76 TP53 (0.38) SLC7A5TP53ALDH1A1HSD17B10KDM4E
SCHEMBL5086037 0.75 TP53 (0.42) SLC7A5TP53ALDH1A1HSD17B10SLC1A3
SCHEMBL10808751 0.73 HIF1A (0.39) SLC7A5TP53ALDH1A1HSD17B10
SCHEMBL1190608 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503506-B2 Dual drug antibody-drug conjugates UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2025-12-23 US disclosed
US-20220249681-A1 DUAL DRUG ANTIBODY-DRUG CONJUGATES UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2022-08-11 US disclosed
EP-3986939-A1 DUAL DRUG ANTIBODY-DRUG CONJUGATES University of Georgia Research Foundation, Inc. (US) 2022-04-27 EP disclosed
WO-2020263943-A1 DUAL DRUG ANTIBODY-DRUG CONJUGATES UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2020-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503506-B2 Dual drug antibody-drug conjugates ABCC1, ABCB1, BCR SLC7A5 827/4885TP53 1010/4885ALDH1A1 269/4885
US-20220249681-A1 DUAL DRUG ANTIBODY-DRUG CONJUGATES ABCC1, ABCB1, BCR SLC7A5 827/4885TP53 1010/4885ALDH1A1 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.